BiotageAB (STO:BIOT) ("Biotage"), the leading global separations Company developing intelligent workflow solutions for drug discovery and development through to diagnostics, has today announced the appointment of Frederic Vanderhaegen as Chief Executive Officer, effective September 16th 2024. Mr. Vanderhaegen succeeds Torben Jørgensen, who stepped in as interim CEO in January 2024 and he will now continue as a board member.
Frederic Vanderhaegen is a prominent life science leader with 30+ years' experience leading complex organisations with portfolios including laboratory products, diagnostics, and medical devices. He is ideally positioned to lead the company through its next ambitious phase of growth.
Commenting on the appointment, Kieran Murphy, Chair of the Board said:
"We are delighted to welcome Frederic Vanderhaegen as the new CEO of Biotage. He brings a wealth of experience and a proven track record of success to the role. We are confident that Frederic will drive a continued phase of growth and deliver significant value to our shareholders. The Board looks forward to supporting him in this exciting new chapter for the company."
On behalf of the board, I would like to thank Torben for his outstanding leadership during this transitional period. His deep knowledge of the business and unwavering commitment to the company over the past almost twenty years, first as CEO and then as Chairman, has been exceptional.
Torben Jørgensen interim CEO and Board Member added:
"I have very much enjoyed working closely with the Biotage team since January and I am delighted with the progress we have made on many fronts. I am excited to have Frederic as the new CEO and am committed to ensuring a smooth handover"
Frederic Vanderhaegen, new CEO, commented:
"I am thrilled to take on the role of CEO at Biotage. This is an exciting time for the company, and I am confident that we can build on our strong foundations and deliver exceptional value to our shareholders, customers, and employees. I look forward to working closely with the talented team and board at Biotage to drive growth and innovation."
Frederic joins Biotage from Avantor where he was General Manager and Executive Vice President for Europe. He also led the global portfolio for the life science business, sourcing and commercial excellence teams. Prior to Avantor, he worked for Ortho Clinical Diagnostics, Danaher, Tecan and Millipore in various senior leadership positions.
Frederic holds a Biochemical Engineering degree from Haute Ecole Lucia Debroeckere, a Chemical and Agricultural Engineering degree from Universite Libre de Bruxelles and an MBA from the Open University.
Contacts
Torben Jörgensen, Interim President & CEO
Tel: +46-707 49 05 84, torben.jorgensen@biotage.com
About Biotage
Biotage is the Global Go-To Separations Company, supporting customers from drug discovery and development through to diagnostics and analytical testing with intelligent and sustainable workflow solutions. Our expertise and top-tier separation solutions play a key role in streamlining our customers' workflows and improving their outcomes.
Headquartered in Sweden, Biotage operates globally with 700 employees, serving over 80 countries. Our company is listed on NASDAQ Stockholm (BIOT).
Website: www.biotage.com
This information is information that Biotage is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-13 07:45 CEST.
